Dear Pharmaceutical Professional,

The acute myeloid leukemia (AML) market will be impacted by data presented during the virtual American Society of Hematology (ASH) meeting. With this year’s new virtual format, do you have a strategy for understanding the commercial impact of breaking data in AML?

As seasoned experts in bringing congress data to hematologists/oncologists in their practice, our team will be working with 30 hem/oncs during the meeting to better understand the commercial implications of data presented for:

    gilteritinib
    azacitidine
    gilteritinib + azacitidine
    CPX-351 + venetoclax
    CC-486
    magrolimab + azacitidine
    azacitidine + decitabine

Order your 60-slide report so you can make better decisions today and prepare for tomorrow.

Sincerely,

The Breaking Data Team

Acute Myeloid Leukemia ASH 2020

American Society of Hematology

Virtual Meeting
December 5 to December 8

Share:

Stay Connected with Hem/Oncs at ASH 2020

Learn More